Iziphumo eziGroundbreaking zeCD7-Targeted CAR-T Therapy ye-T-ALL kunye ne-T-LBL

Ulingo lwezonyango lwakutsha nje lubonise ukuqhubela phambili okubonakalayo kunyango lwe-T-cell acute lymphoblastic leukemia (T-ALL) kunye ne-T-cell lymphoblastic lymphoma (T-LBL) esebenzisa iCD7-targeted chimeric antigen receptor (CAR) T cell therapy. . Uphononongo, oluqhutywe liqela elivela kwiSibhedlele saseHebei Yanda Lu Daopei kunye neLu Daopei Institute of Hematology, libandakanya izigulane ze-60 ezifumene idosi enye yeeseli ezikhethiweyo ze-CD7 CAR (NS7CAR) T ezikhethiweyo ngokwemvelo.

Iziphumo zolingo ziyakhuthaza kakhulu. Ngomhla we-28, i-94.4% yezigulane zifumene ukuxolelwa okupheleleyo (CR) kumongo wethambo. Ukongezelela, phakathi kwezigulane ze-32 ezinesifo se-extramedullary, i-78.1% ibonise impendulo efanelekileyo, kunye ne-56.3% iphumelele uxolelo olupheleleyo kunye ne-21.9% iphumelele ukuxolelwa ngokuyinxenye. Amazinga okusinda eminyaka emibini ewonke kunye namazinga okusinda ngaphandle kokuqhubekeka ayengama-63.5% kunye nama-53.7%, ngokulandelelanayo.

Olu nyango oluhlaziyiweyo luphawuleka kwiprofayili yokhuseleko olulawulekayo, kunye ne-cytokine release syndrome eyenzeka kwi-91.7% yezigulane (ininzi ibakala 1 / 2), kunye ne-neurotoxicity ebonwe kwi-5% yamatyala. Ngaphezu koko, uphando lufumene ukuba izigulane eziqhubekile nokufakelwa kokudibanisa emva kokufumana i-CR zinezinga eliphezulu lokusinda ngaphandle kwenkqubela xa kuthelekiswa nalabo abangazange baphumelele.

Inkampani yethu ikwaphonononga ukubanakho konyango lweeseli ze-CD7 CAR-T kunye nemveliso yethu yobunini, ijolise ekubeni negalelo ekuqhubeleni phambili unyango lwe-T-cell malignancies.

Ezi ziphumo zigxininisa amandla onyango lwe-CD7-ejoliswe kwi-CAR-T yeseli ukunika ithemba elitsha kwizigulane ezine-T-ALL kunye ne-T-LBL ezichasayo okanye ezibuyele kwi-T-LBL, okuphawula isiganeko esibalulekileyo kwidabi eliqhubekayo lokulwa nezi zifo zingumngeni.